HC Wainwright Reiterates Buy Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $32.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 55.11% from the company’s current price.

Several other research analysts have also weighed in on KURA. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. JMP Securities raised their price target on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a research report on Wednesday, January 31st. Finally, Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.28.

Kura Oncology Stock Up 0.2 %

Shares of NASDAQ:KURA traded up $0.04 during trading on Friday, hitting $20.63. The company’s stock had a trading volume of 605,625 shares, compared to its average volume of 831,868. The company has a market capitalization of $1.57 billion, a PE ratio of -9.51 and a beta of 0.89. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.26 and a current ratio of 12.26. The stock’s 50-day moving average price is $20.66 and its two-hundred day moving average price is $15.99.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, May 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). During the same quarter in the prior year, the business earned ($0.50) earnings per share. Kura Oncology’s revenue was up .0% on a year-over-year basis. As a group, sell-side analysts expect that Kura Oncology will post -2.35 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale increased its stake in Kura Oncology by 216.7% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 95,000 shares of the company’s stock valued at $1,343,000 after buying an additional 65,000 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Kura Oncology by 18.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 563,421 shares of the company’s stock worth $5,138,000 after purchasing an additional 86,141 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Kura Oncology by 10.9% in the third quarter. Bank of New York Mellon Corp now owns 261,744 shares of the company’s stock worth $2,387,000 after purchasing an additional 25,677 shares during the period. Jupiter Asset Management Ltd. boosted its stake in Kura Oncology by 234.2% during the 3rd quarter. Jupiter Asset Management Ltd. now owns 57,877 shares of the company’s stock valued at $528,000 after purchasing an additional 40,560 shares in the last quarter. Finally, Walleye Capital LLC increased its position in shares of Kura Oncology by 220.4% during the 3rd quarter. Walleye Capital LLC now owns 264,893 shares of the company’s stock valued at $2,416,000 after purchasing an additional 182,221 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.